Unexpected Hypereosinophilia after Sinopharm Vaccination: A Case Report

COVID-19 vaccines have been associated with various adverse events, though their safety profile is generally favorable. We present a case of a 66-year-old male who developed hypereosinophilia (Absolute eosinophil count: 4063 cells/µL) and lymphadenopathy following the third dose of the Sinopharm COVID-19 vaccine. Despite extensive investigations, an underlying cause for these findings was not identified. While a causal relationship cannot be definitively established, the temporal association between the vaccine and symptom onset is intriguing. This case highlights the importance of continued surveillance for rare adverse events following vaccination and emphasizes the need for further research to understand the potential mechanisms linking COVID-19 vaccines to eosinophilic disorders.